News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Daily News PREVENT Risk Calculator Works Well in Patients With High and Low Lp(a) Michael O'Riordan June 10, 2025
News Daily News High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low Michael O'Riordan November 13, 2024
News Daily News Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime Michael O'Riordan October 14, 2024
News Conference News ESC 2024 Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events Caitlin E. Cox August 31, 2024
News Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia Michael O'Riordan May 30, 2024
News Daily News Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups Michael O'Riordan April 17, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Daily News High Lp(a) Levels Harmful in Patients With and Without ASCVD Michael O'Riordan February 27, 2024
News Daily News Less Is More: Lp(a) Much More Atherogenic Than LDL Michael O'Riordan January 16, 2024
News Conference News AHA 2023 Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study Michael O'Riordan November 13, 2023
News Daily News Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death Michael O'Riordan July 07, 2023
News Daily News Oxidized Phospholipids and Lp(a) Strongly Associated With MACE: CASABLANCA Michael O'Riordan May 03, 2023
News Daily News How Lp(a) Levels Compare With LDL-C in FH: Some Surprises Michael O'Riordan November 17, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022